ArticleInternational journal of particle therapy2026
The Use of Protons in the Management of Recurrent, Previously Irradiated Adenoid Cystic Carcinoma.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Introduction: Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy with a high risk of perineural invasion, local recurrence, and distant metastasis. Recurrent ACC poses unique challenges due to its aggressive nature, resection limited by morbidity, and prior radiation. Proton therapy, with its ability to spare normal tissues via the Bragg peak, may offer a promising and safe re-irradiation approach, especially in patients not amenable to resection requiring high definitive doses. The purpose of this study was to evaluate outcomes of patients with recurrent ACC treated with proton radiation. Methods: We reviewed the records of all patients with recurrent head and neck ACC treated with proton therapy between November 2012 and December 2023. This cohort included patients with both resected and unresected disease. Standard imaging, including MRI for perineural spread and PET for distant recurrence, was used in all cases. Descriptive statistics were used to analyze patient, tumor, and treatment characteristics, and the Kaplan-Meier method and cumulative incidence curves were utilized to estimate overall survival (OS) and loco-regional recurrence (LRR), respectively. Results: A total of 19 patients were included, with 6 (32%) receiving adjuvant re-irradiation and 13 (68%) receiving definitive proton re-irradiation. Median dose in the adjuvant group was 63.36 (59.40-70.07), and 59.20 (14.80-70.00) in the primary RT group. The median OS for all patients was 62% at 24 months and 48% at 48 months. Patients receiving adjuvant therapy had an OS of 80% at 24 and 48 months, while those not receiving surgery had an OS of 52% and 31% at 24- and 48-months. LRR at 24 months was 11% for all patients. No grade 5 toxicities were observed. Conclusion: This study demonstrates the feasibility and potential benefits of proton re-irradiation for recurrent ACC, with promising local-regional control and minimal toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.